Published in Mol Cancer Ther on December 30, 2015
Synthetic genome readers target clustered binding sites across diverse chromatin states. Proc Natl Acad Sci U S A (2016) 0.75
Cancer statistics, 2013. CA Cancer J Clin (2013) 84.72
TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol (2013) 32.42
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol (2014) 27.48
Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A (1995) 24.77
Open source clustering software. Bioinformatics (2004) 23.17
Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell (2008) 13.49
Drug-target network. Nat Biotechnol (2007) 11.15
The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer (1955) 10.49
HIF-1 alpha is required for solid tumor formation and embryonic vascularization. EMBO J (1998) 10.08
Lysyl oxidase is essential for hypoxia-induced metastasis. Nature (2006) 8.28
Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res (1997) 7.95
Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer (2004) 7.91
Targeting hypoxia in cancer therapy. Nat Rev Cancer (2011) 7.10
Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev (2007) 6.91
HIF-independent regulation of VEGF and angiogenesis by the transcriptional coactivator PGC-1alpha. Nature (2008) 5.85
PrimerBank: a resource of human and mouse PCR primer pairs for gene expression detection and quantification. Nucleic Acids Res (2009) 5.03
Hypoxia-inducible nuclear factors bind to an enhancer element located 3' to the human erythropoietin gene. Proc Natl Acad Sci U S A (1991) 4.84
Patient-derived tumour xenografts as models for oncology drug development. Nat Rev Clin Oncol (2012) 4.00
Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway. Cancer Cell (2004) 3.43
Use of an orthotopic xenograft model for assessing the effect of epidermal growth factor receptor amplification on glioblastoma radiation response. Clin Cancer Res (2006) 3.15
Unravelling the complexity of metastasis - molecular understanding and targeted therapies. Nat Rev Cancer (2011) 2.64
Oxygen sensing, hypoxia-inducible factors, and disease pathophysiology. Annu Rev Pathol (2013) 2.44
Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization. Proc Natl Acad Sci U S A (2009) 2.33
Inhibition of vascular endothelial growth factor with a sequence-specific hypoxia response element antagonist. Proc Natl Acad Sci U S A (2004) 2.25
Antiangiogenic therapy and tumor progression. Cancer Cell (2004) 2.20
Hypoxia-induced autophagy promotes tumor cell survival and adaptation to antiangiogenic treatment in glioblastoma. Cancer Res (2012) 2.12
Development of HIF-1 inhibitors for cancer therapy. J Cell Mol Med (2009) 2.09
Suppression of androgen receptor-mediated gene expression by a sequence-specific DNA-binding polyamide. Proc Natl Acad Sci U S A (2007) 2.04
Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cells. Proc Natl Acad Sci U S A (2009) 1.95
Modulating hypoxia-inducible transcription by disrupting the HIF-1-DNA interface. ACS Chem Biol (2007) 1.84
Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition. Mol Cancer Ther (2009) 1.67
Completion of a Programmable DNA-Binding Small Molecule Library. Tetrahedron (2007) 1.58
Mechanisms of resistance to anti-angiogenic therapy and development of third-generation anti-angiogenic drug candidates. Genes Cancer (2010) 1.54
Hypoxia inducible factor-1 independent pathways in tumor angiogenesis. Clin Cancer Res (2007) 1.44
Current review of in vivo GBM rodent models: emphasis on the CNS-1 tumour model. ASN Neuro (2011) 1.44
Modulation of NF-κB-dependent gene transcription using programmable DNA minor groove binders. Proc Natl Acad Sci U S A (2011) 1.36
Promiscuous drugs compared to selective drugs (promiscuity can be a virtue). BMC Clin Pharmacol (2005) 1.34
New insights into the biology of renal cell carcinoma. Hematol Oncol Clin North Am (2011) 1.31
Antitumor activity of a pyrrole-imidazole polyamide. Proc Natl Acad Sci U S A (2013) 1.13
Hypoxia-inducible factor-1 as a therapeutic target in cancer. J Gastroenterol Hepatol (2013) 1.10
Pharmacokinetics of Py-Im polyamides depend on architecture: cyclic versus linear. J Am Chem Soc (2012) 1.03
Blood flow in six human melanoma xenograft lines with different growth characteristics. Cancer Res (1992) 1.01
In vivo modulation of hypoxia-inducible signaling by topographical helix mimetics. Proc Natl Acad Sci U S A (2014) 1.01
Cancer systems biology: embracing complexity to develop better anticancer therapeutic strategies. Oncogene (2014) 1.00
Single-dose pharmacokinetic and toxicity analysis of pyrrole-imidazole polyamides in mice. Cancer Chemother Pharmacol (2012) 0.97
Activity of a Py-Im polyamide targeted to the estrogen response element. Mol Cancer Ther (2013) 0.92
Animal toxicity of hairpin pyrrole-imidazole polyamides varies with the turn unit. J Med Chem (2013) 0.83
Replication stress by Py-Im polyamides induces a non-canonical ATR-dependent checkpoint response. Nucleic Acids Res (2014) 0.81
A C-14 labeled Py-Im polyamide localizes to a subcutaneous prostate cancer tumor. Bioorg Med Chem (2014) 0.80
Tumor xenograft uptake of a pyrrole-imidazole (Py-Im) polyamide varies as a function of cell line grafted. J Med Chem (2014) 0.76
A Pyrrole-Imidazole Polyamide Is Active against Enzalutamide-Resistant Prostate Cancer. Cancer Res (2017) 0.75